Drugs / CS060380
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06573528 | Sep 2024 → May 2025 | — | Cascade Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07466017 | Apr 2026 → Apr 2027 expected | metabolic dysfunction-associated steatohepatitis, obesity disorder | Cascade Pharmaceuticals, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT07198386 | Sep 2025 → Jul 2026 overdue | metabolic dysfunction-associated steatohepatitis | Cascade Pharmaceuticals, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS060380 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07198386 ↗ |
| Route | Oral | “Tablets administered orally” NCT06573528 ↗ |